
    
      Patients will receive AZD9291 at a dose of 80 mg once daily. Systemic evaluation will be done
      by PET-CT scan after 6 weeks.

      In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks. Non-responding
      patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of
      response assessment at each time-point). All the patients will be followed for 2 years.

      The imaging modality used for RECIST v1.1 assessments will be PET-CT scan.
    
  